Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study.1 passage
• A global view of pulmonary hypertension.1 passage
• A novel endpoint for exacerbations in asthma to accelerate clinical development: a post-hoc analysis of randomised controlled trials.1 passage
• A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial.1 passage
• A tricompartmental model of lung oxygenation disruption to explain pulmonary and systemic pathology in severe COVID-19.1 passage
• Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.1 passage
• Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain.1 passage
• Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial.1 passage
• Acute respiratory failure in immunocompromised adults.1 passage
• Added value of combined endobronchial and oesophageal endosonography for mediastinal nodal staging in lung cancer: a systematic review and meta-analysis.1 passage
• Addressing the post-acute sequelae of SARS-CoV-2 infection: a multidisciplinary model of care.1 passage
• Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.1 passage
• Advances in understanding and reducing the burden of severe asthma in children.1 passage
• Advancing precision medicine for acute respiratory distress syndrome.1 passage
• Aetiology of childhood pneumonia in a well vaccinated South African birth cohort: a nested case-control study of the Drakenstein Child Health Study.1 passage
• Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000-18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database.1 passage
• Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial.1 passage
• Airway management complications in children with difficult tracheal intubation from the Pediatric Difficult Intubation (PeDI) registry: a prospective cohort analysis.1 passage
• Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.1 passage
• Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.1 passage
• Aligning use of intensive care with patient values in the USA: past, present, and future.1 passage
• Allergic diseases and the effect of inhaled epinephrine in children with acute bronchiolitis: follow-up from the randomised, controlled, double-blind, Bronchiolitis ALL trial.1 passage
• Allocating scarce intensive care resources during the COVID-19 pandemic: practical challenges to theoretical frameworks.1 passage
• An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study.1 passage
• Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study.1 passage
• Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis.1 passage
• Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?1 passage
• Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial.1 passage
• Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.1 passage
• Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial.1 passage
• Assessing the strength of evidence for a causal effect of respiratory syncytial virus lower respiratory tract infections on subsequent wheezing illness: a systematic review and meta-analysis.1 passage
• Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.1 passage
• Association between driving pressure and development of postoperative pulmonary complications in patients undergoing mechanical ventilation for general anaesthesia: a meta-analysis of individual patient data.1 passage
• Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study.1 passage
• Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.1 passage
• Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort.1 passage
• Asthma transition from childhood into adulthood.1 passage
• Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.1 passage
• Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial.1 passage
• Azithromycin for episodes with asthma-like symptoms in young children aged 1-3 years: a randomised, double-blind, placebo-controlled trial.1 passage
• Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial.1 passage
• BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis.1 passage
• BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.1 passage
• Bacterial and viral respiratory tract microbiota and host characteristics in children with lower respiratory tract infections: a matched case-control study.1 passage
• Balancing the needs of the many and the few: where next for adult asthma guidelines?1 passage
• Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis.1 passage
• Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.1 passage
• Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.1 passage
• Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial.1 passage
• Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19.1 passage
• Beyond the guidelines for non-invasive ventilation in acute respiratory failure: implications for practice.1 passage
• Biomarker-guided antibiotic stewardship in suspected ventilator-associated pneumonia (VAPrapid2): a randomised controlled trial and process evaluation.1 passage
• Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study.1 passage
• Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial.1 passage
• Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis.1 passage
• Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study.1 passage
• Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.1 passage
• Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.1 passage
• Blood transcriptional biomarkers for active pulmonary tuberculosis in a high-burden setting: a prospective, observational, diagnostic accuracy study.1 passage
• Bronchial thermoplasty and biological therapy as targeted treatments for severe uncontrolled asthma.1 passage
• Bronchiectasis: new therapies and new perspectives.1 passage
• Bubble continuous positive airway pressure for children with high-risk conditions and severe pneumonia in Malawi: an open label, randomised, controlled trial.1 passage
• Burden of asthma and chronic obstructive pulmonary disease and access to essential medicines in low-income and middle-income countries.1 passage
• Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis.1 passage
• Burden of tuberculosis in intensive care units in Cape Town, South Africa, and assessment of the accuracy and effect on patient outcomes of the Xpert MTB/RIF test on tracheal aspirate samples for diagnosis of pulmonary tuberculosis: a prospective burden of disease study with a nested randomised controlled trial.1 passage
• COVID-19 among people experiencing homelessness in England: a modelling study.1 passage
• COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study.1 passage
• COVID-19-associated Aspergillus tracheobronchitis: the interplay between viral tropism, host defence, and fungal invasion.1 passage
• COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?1 passage
• CT imaging of chronic obstructive pulmonary disease: insights, disappointments, and promise.1 passage
• CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.1 passage
• Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.1 passage
• Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease.1 passage
• Cardiac effects of current treatments of chronic obstructive pulmonary disease.1 passage
• Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study.1 passage
• Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study.1 passage
• Challenges in the diagnosis of paediatric pneumonia in intervention field trials: recommendations from a pneumonia field trial working group.1 passage
• Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK.1 passage
• Changes in lung function in European adults born between 1884 and 1996 and implications for the diagnosis of lung disease: a cross-sectional analysis of ten population-based studies.1 passage
• Characterisation of the first 250,000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data.1 passage
• Childhood asthma prediction models: a systematic review.1 passage
• Childhood predictors of lung function trajectories and future COPD risk: a prospective cohort study from the first to the sixth decade of life.1 passage
• Chronic obstructive pulmonary disease and related phenotypes: polygenic risk scores in population-based and case-control cohorts.1 passage
• Chronic obstructive pulmonary disease in China: a nationwide prevalence study.1 passage
• Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study.1 passage
• Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study.1 passage
• Classification of usual interstitial pneumonia in patients with interstitial lung disease: assessment of a machine learning approach using high-dimensional transcriptional data.1 passage
• Clinical characteristics and outcomes of invasively ventilated patients with COVID-19 in Argentina (SATICOVID): a prospective, multicentre cohort study.1 passage
• Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.1 passage
• Clinical impact of a routine, molecular, point-of-care, test-and-treat strategy for influenza in adults admitted to hospital (FluPOC): a multicentre, open-label, randomised controlled trial.1 passage
• Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study.1 passage
• Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study.1 passage
• Clinical phenotypes of delirium during critical illness and severity of subsequent long-term cognitive impairment: a prospective cohort study.1 passage
• Clinical trials in acute respiratory distress syndrome: challenges and opportunities.1 passage
• Clinical trials in critical care: can a Bayesian approach enhance clinical and scientific decision making?1 passage
• Cognitive decline after sepsis.1 passage
• Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial.1 passage
• Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.1 passage
• Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis.1 passage
• Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study.1 passage
• Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study.1 passage
• Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial.1 passage
• Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.1 passage
• Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study.1 passage
• Comparison of the effects of continuous positive airway pressure and mandibular advancement devices on sleepiness in patients with obstructive sleep apnoea: a network meta-analysis.1 passage
• Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial.1 passage
• Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis.1 passage
• Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses.1 passage
• Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.1 passage
• Continuous positive airway pressure versus standard care for the treatment of people with mild obstructive sleep apnoea (MERGE): a multicentre, randomised controlled trial.1 passage
• Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations.1 passage
• Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.1 passage
• Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial.1 passage
• Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial.1 passage
• Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes.1 passage
• DNA methylation in childhood asthma: an epigenome-wide meta-analysis.1 passage
• DNA methylation in nasal epithelium, atopy, and atopic asthma in children: a genome-wide study.1 passage
• Decreasing antibiotic use, the gut microbiota, and asthma incidence in children: evidence from population-based and prospective cohort studies.1 passage
• Deep learning for classifying fibrotic lung disease on high-resolution computed tomography: a case-cohort study.1 passage
• Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.1 passage
• Determining the outcomes of interventions to prevent respiratory syncytial virus disease in children: what to measure?1 passage
• Development and internal validation of a clinical rule to improve antibiotic use in children presenting to primary care with acute respiratory tract infection and cough: a prognostic cohort study.1 passage
• Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials.1 passage
• Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study.1 passage
• Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial.1 passage
• Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy.1 passage
• Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis.1 passage
• Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study.1 passage
• Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial.1 passage
• Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper.1 passage
• Diaphragmatic myotrauma: a mediator of prolonged ventilation and poor patient outcomes in acute respiratory failure.1 passage
• Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial.1 passage
• Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?1 passage
• Does inhaled steroid therapy help emerging asthma in early childhood?1 passage
• Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.1 passage
• Doxycycline for outpatient-treated acute exacerbations of COPD: a randomised double-blind placebo-controlled trial.1 passage
• Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.1 passage
• Duration of amoxicillin-clavulanate for protracted bacterial bronchitis in children (DACS): a multi-centre, double blind, randomised controlled trial.1 passage
• Dynamic light application therapy to reduce the incidence and duration of delirium in intensive-care patients: a randomised controlled trial.1 passage
• E-cigarette, or vaping, product use associated lung injury (EVALI): case series and diagnostic approach.1 passage
• E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis.1 passage
• ECMO for severe ARDS associated with COVID-19: now we know we can, but should we?1 passage
• Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities.1 passage
• Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries.1 passage
• Early-life exposure to electronic cigarettes: cause for concern.1 passage
• Early-onset emphysema in a large French-Canadian family: a genetic investigation.1 passage
• Effect of a Russian-backbone live-attenuated influenza vaccine with an updated pandemic H1N1 strain on shedding and immunogenicity among children in The Gambia: an open-label, observational, phase 4 study.1 passage
• Effect of a fluid bolus on cardiovascular collapse among critically ill adults undergoing tracheal intubation (PrePARE): a randomised controlled trial.1 passage
• Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study.1 passage
• Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial.1 passage
• Effect of an electronic nicotine delivery system with 0, 8, or 36 mg/mL liquid nicotine versus a cigarette substitute on tobacco-related toxicant exposure: a four-arm, parallel-group, randomised, controlled trial.1 passage
• Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial.1 passage
• Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.1 passage
• Effect of aspirin on deaths associated with sepsis in healthy older people (ANTISEPSIS): a randomised, double-blind, placebo-controlled primary prevention trial.1 passage
• Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study.1 passage
• Effect of early parenteral nutrition during paediatric critical illness on DNA methylation as a potential mediator of impaired neurocognitive development: a pre-planned secondary analysis of the PEPaNIC international randomised controlled trial.1 passage
• Effect of early supplemental parenteral nutrition in the paediatric ICU: a preplanned observational study of post-randomisation treatments in the PEPaNIC trial.1 passage
• Effect of early versus late or no tracheostomy on mortality and pneumonia of critically ill patients receiving mechanical ventilation: a systematic review and meta-analysis.1 passage
• Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.1 passage
• Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study.1 passage
• Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.1 passage
• Effect of non-invasive oxygenation strategies in immunocompromised patients with severe acute respiratory failure: a post-hoc analysis of a randomised trial.1 passage
• Effect of obstructive sleep apnoea and its treatment with continuous positive airway pressure on the prevalence of cardiovascular events in patients with acute coronary syndrome (ISAACC study): a randomised controlled trial.1 passage
• Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.1 passage
• Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial.1 passage
• Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.1 passage
• Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study.1 passage
• Effectiveness of WHO's pragmatic screening algorithm for child contacts of tuberculosis cases in resource-constrained settings: a prospective cohort study in Uganda.1 passage
• Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials.1 passage
• Effectiveness of influenza vaccination on influenza-associated hospitalisations over time among children in Hong Kong: a test-negative case-control study.1 passage
• Effectiveness of seasonal influenza vaccination in community-dwelling elderly people: an individual participant data meta-analysis of test-negative design case-control studies.1 passage
• Effects of saline or albumin fluid bolus in resuscitation: evidence from re-analysis of the FEAST trial.1 passage
• Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial.1 passage
• Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.1 passage
• Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.1 passage
• Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.1 passage
• Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.1 passage
• Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.1 passage
• Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial.1 passage
• Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.1 passage
• Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.1 passage
• Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.1 passage
• Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.1 passage
• Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.1 passage
• Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study.1 passage
• Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial.1 passage
• Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.1 passage
• Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial.1 passage
• Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.1 passage
• Efficacy of oral amoxicillin-clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial.1 passage
• Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.1 passage
• Efficacy, duration of protection, birth outcomes, and infant growth associated with influenza vaccination in pregnancy: a pooled analysis of three randomised controlled trials.1 passage
• Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.1 passage
• Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.1 passage
• Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.1 passage
• Enhanced understanding of the host-pathogen interaction in sepsis: new opportunities for omic approaches.1 passage
• Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial.1 passage
• Eosinophils in COPD: just another biomarker?1 passage
• Epidemiological characteristics, practice of ventilation, and clinical outcome in patients at risk of acute respiratory distress syndrome in intensive care units from 16 countries (PRoVENT): an international, multicentre, prospective study.1 passage
• Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.1 passage
• Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.1 passage
• Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.1 passage
• Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis.1 passage
• Evaluation of early administration of simvastatin in the prevention and treatment of delirium in critically ill patients undergoing mechanical ventilation (MoDUS): a randomised, double-blind, placebo-controlled trial.1 passage
• Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis.1 passage
• Expiratory airflow in late adolescence and early adulthood in individuals born very preterm or with very low birthweight compared with controls born at term or with normal birthweight: a meta-analysis of individual participant data.1 passage
• Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study.1 passage
• Exposure to air pollution and development of asthma and rhinoconjunctivitis throughout childhood and adolescence: a population-based birth cohort study.1 passage
• Expression quantitative trait locus fine mapping of the 17q12-21 asthma locus in African American children: a genetic association and gene expression study.1 passage
• Extracorporeal carbon dioxide removal for lowering the risk of mechanical ventilation: research questions and clinical potential for the future.1 passage
• Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study.1 passage
• Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study.1 passage
• Factors associated with failure of emergency department management in children with acute moderate or severe asthma: a prospective, multicentre, cohort study.1 passage
• Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study.1 passage
• Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.1 passage
• Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial.1 passage
• Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.1 passage
• Functional effects of the microbiota in chronic respiratory disease.1 passage
• Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study.1 passage
• Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.1 passage
• Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis.1 passage
• Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study.1 passage
• Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study.1 passage
• Genome-wide expression for diagnosis of pulmonary tuberculosis: a multicohort analysis.1 passage
• Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study.1 passage
• Geo-economic variations in epidemiology, patterns of care, and outcomes in patients with acute respiratory distress syndrome: insights from the LUNG SAFE prospective cohort study.1 passage
• Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019.1 passage
• Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.1 passage
• Growth in children with pulmonary arterial hypertension: a longitudinal retrospective multiregistry study.1 passage
• Heterogeneity of chronic obstructive pulmonary disease exacerbations: a two-axes classification proposal.1 passage
• Hydroxyethyl starch versus saline for resuscitation of patients in intensive care: long-term outcomes and cost-effectiveness analysis of a cohort from CHEST.1 passage
• Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial.1 passage
• Hypoxic pulmonary hypertension in chronic lung diseases: novel vasoconstrictor pathways.1 passage
• Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial.1 passage
• Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.1 passage
• Identification of children at risk of influenza-related complications in primary and ambulatory care: a systematic review and meta-analysis.1 passage
• Identification of phenotypes in paediatric patients with acute respiratory distress syndrome: a latent class analysis.1 passage
• Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations.1 passage
• Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities.1 passage
• Imaging research in fibrotic lung disease; applying deep learning to unsolved problems.1 passage
• Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial.1 passage
• Immediate interruption of sedation compared with usual sedation care in critically ill postoperative patients (SOS-Ventilation): a randomised, parallel-group clinical trial.1 passage
• Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study.1 passage
• Immunomodulation by macrolides: therapeutic potential for critical care.1 passage
• Incidence and prognosis of ventilator-associated tracheobronchitis (TAVeM): a multicentre, prospective, observational study.1 passage
• Incidence of medically attended influenza during pandemic and post-pandemic seasons through the Influenza Incidence Surveillance Project, 2009-13.1 passage
• Incidence of severe critical events in paediatric anaesthesia (APRICOT): a prospective multicentre observational study in 261 hospitals in Europe.1 passage
• Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort study.1 passage
• Individualised oxygen delivery targeted haemodynamic therapy in high-risk surgical patients: a multicentre, randomised, double-blind, controlled, mechanistic trial.1 passage
• Individualised perioperative open-lung approach versus standard protective ventilation in abdominal surgery (iPROVE): a randomised controlled trial.1 passage
• Induced hypothermia in patients with septic shock and respiratory failure (CASS): a randomised, controlled, open-label trial.1 passage
• Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial.1 passage
• Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.1 passage
• Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial.1 passage
• Inhaled isoflurane via the anaesthetic conserving device versus propofol for sedation of invasively ventilated patients in intensive care units in Germany and Slovenia: an open-label, phase 3, randomised controlled, non-inferiority trial.1 passage
• Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.1 passage
• Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study.1 passage
• Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study.1 passage
• Insights and challenges in tuberculosis vaccine development.1 passage
• Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations.1 passage
• Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context.1 passage
• Interleukin-6: obstacles to targeting a complex cytokine in critical illness.1 passage
• Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society.1 passage
• Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial.1 passage
• Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial.1 passage
• Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial.1 passage
• Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study.1 passage
• Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.1 passage
• Is there a causal relationship between respiratory syncytial virus lower respiratory tract infection and chronic wheezing?1 passage
• Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study.1 passage
• Juntos en la pandemia de COVID-19 (together in the COVID-19 pandemic): health-care professionals and the Latinx community.1 passage
• Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial.1 passage
• Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial.1 passage
• Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial.1 passage
• Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial.1 passage
• Long-term developmental effects of withholding parenteral nutrition for 1 week in the paediatric intensive care unit: a 2-year follow-up of the PEPaNIC international, randomised, controlled trial.1 passage
• Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE).1 passage
• Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis.1 passage
• Long-term non-invasive ventilation in children.1 passage
• Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the Copenhagen City Heart study: a prospective population-based analysis.1 passage
• Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial.1 passage
• Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study.1 passage
• Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.1 passage
• Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.1 passage
• Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.1 passage
• Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study.1 passage
• Long-term survival of critically ill patients treated with prolonged mechanical ventilation: a systematic review and meta-analysis.1 passage
• Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study.1 passage
• Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study.1 passage
• Longitudinal respiratory subphenotypes in patients with COVID-19-related acute respiratory distress syndrome: results from three observational cohorts.1 passage
• Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics.1 passage
• Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trial.1 passage
• Lung cancer screening: latest developments and unanswered questions.1 passage
• Lung disease in primary antibody deficiency.1 passage
• Lung function decline in former smokers and low-intensity current smokers: a secondary data analysis of the NHLBI Pooled Cohorts Study.1 passage
• Lung function in early adulthood and health in later life: a transgenerational cohort analysis.1 passage
• Lung function trajectories from pre-school age to adulthood and their associations with early life factors: a retrospective analysis of three population-based birth cohort studies.1 passage
• Lung function trajectories in health and disease.1 passage
• Lung microbiota predict chronic rejection in healthy lung transplant recipients: a prospective cohort study.1 passage
• Lung recruitment before surfactant administration in extremely preterm neonates with respiratory distress syndrome (IN-REC-SUR-E): a randomised, unblinded, controlled trial.1 passage
• Lung transplantation for idiopathic pulmonary fibrosis.1 passage
• Lung volume reduction for emphysema.1 passage
• Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management.1 passage
• Machine learning for real-time prediction of complications in critical care: a retrospective study.1 passage
• Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.1 passage
• Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial.1 passage
• Malignant pleural effusion management: keeping the flood gates shut.1 passage
• Management of acute kidney injury in patients with COVID-19.1 passage
• Management of chronic obstructive pulmonary disease beyond the lungs.1 passage
• Mechanisms underlying increased mortality risk in patients with heart failure and reduced ejection fraction randomly assigned to adaptive servoventilation in the SERVE-HF study: results of a secondary multistate modelling analysis.1 passage
• Meeting the challenge of COPD care delivery in the USA: a multiprovider perspective.1 passage
• Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial.1 passage
• Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial.1 passage
• Mild obstructive sleep apnoea: clinical relevance and approaches to management.1 passage
• Mildly elevated pulmonary artery systolic pressure on echocardiography: bridging the gap in current guidelines.1 passage
• Moderate-to-severe asthma in individuals of European ancestry: a genome-wide association study.1 passage
• Molecular mechanisms underlying variations in lung function: a systems genetics analysis.1 passage
• Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data.1 passage
• Mortality prediction in intensive care units with the Super ICU Learner Algorithm (SICULA): a population-based study.1 passage
• Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017.1 passage
• Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study.1 passage
• Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.1 passage
• National burden estimates of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in 2019 among 58 countries: a modelling study.1 passage
• Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial.1 passage
• Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.1 passage
• Neuromuscular electrical stimulation to improve exercise capacity in patients with severe COPD: a randomised double-blind, placebo-controlled trial.1 passage
• Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study.1 passage
• New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches.1 passage
• Newborn screening for cystic fibrosis.1 passage
• Nicotine patches used in combination with e-cigarettes (with and without nicotine) for smoking cessation: a pragmatic, randomised trial.1 passage
• Nicotine patches with e-cigarettes for smoking cessation: Twitter discussion from a respirology journal club - Authors' reply.1 passage
• Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.1 passage
• Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.1 passage
• Non-invasive respiratory support in the management of acute COVID-19 pneumonia: considerations for clinical practice and priorities for research.1 passage
• Non-invasive ventilation versus high-flow nasal cannula oxygen therapy with apnoeic oxygenation for preoxygenation before intubation of patients with acute hypoxaemic respiratory failure: a randomised, multicentre, open-label trial.1 passage
• Non-tuberculous mycobacteria in children: muddying the waters of tuberculosis diagnosis.1 passage
• Normal polysomnography parameters in healthy adults: a systematic review and meta-analysis.1 passage
• Normothermic ex-vivo preservation with the portable Organ Care System Lung device for bilateral lung transplantation (INSPIRE): a randomised, open-label, non-inferiority, phase 3 study.1 passage
• Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK Biobank.1 passage
• Novel translational approaches to the search for precision therapies for acute respiratory distress syndrome.1 passage
• Occupational lung diseases: from old and novel exposures to effective preventive strategies.1 passage
• On the cutting edge of obstructive sleep apnoea: where next?1 passage
• Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study.1 passage
• Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.1 passage
• Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.1 passage
• Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.1 passage
• Optimising clinical trials in acute myocardial infarction complicated by cardiogenic shock: a statement from the 2020 Critical Care Clinical Trialists Workshop.1 passage
• Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study.1 passage
• Oral prednisolone in preschool children with virus-associated wheeze: a prospective, randomised, double-blind, placebo-controlled trial.1 passage
• Outcomes after transplantation of lungs preserved for more than 12 h: a retrospective study.1 passage
• Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study.1 passage
• Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study.1 passage
• Paediatric acute respiratory distress syndrome incidence and epidemiology (PARDIE): an international, observational study.1 passage
• Paediatric tuberculosis transmission outside the household: challenging historical paradigms to inform future public health strategies.1 passage
• Palliative care in interstitial lung disease: living well.1 passage
• Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial.1 passage
• Particle sizes of infectious aerosols: implications for infection control.1 passage
• Pathological findings in suspected cases of e-cigarette, or vaping, product use-associated lung injury (EVALI): a case series.1 passage
• Pathophysiological role of respiratory dysbiosis in hospital-acquired pneumonia.1 passage
• Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study.1 passage
• Patient factors and temporal trends associated with COVID-19 in-hospital mortality in England: an observational study using administrative data.1 passage
• Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial.1 passage
• Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.1 passage
• Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial.1 passage
• Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.1 passage
• Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503).1 passage
• Permissive hypercapnia in extremely low birthweight infants (PHELBI): a randomised controlled multicentre trial.1 passage
• Personalised mechanical ventilation tailored to lung morphology versus low positive end-expiratory pressure for patients with acute respiratory distress syndrome in France (the LIVE study): a multicentre, single-blind, randomised controlled trial.1 passage
• Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study.1 passage
• Physiotherapy breathing retraining for asthma: a randomised controlled trial.1 passage
• Pirfenidone in patients with non-IPF progressive fibrotic interstitial lung diseases: expert guidance is urgently needed.1 passage
• Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.1 passage
• Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.1 passage
• Pitfalls and caveats in α1-antitrypsin deficiency testing: a guide for clinicians.1 passage
• Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases.1 passage
• Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts.1 passage
• Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study.1 passage
• Pleural infection: past, present, and future directions.1 passage
• Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: a prospective multicentre cohort study.1 passage
• Portable normothermic ex-vivo lung perfusion, ventilation, and functional assessment with the Organ Care System on donor lung use for transplantation from extended-criteria donors (EXPAND): a single-arm, pivotal trial.1 passage
• Post-anaesthesia pulmonary complications after use of muscle relaxants (POPULAR): a multicentre, prospective observational study.1 passage
• Post-mortem lung tissue: the fossil record of the pathophysiology and immunopathology of severe COVID-19.1 passage
• Postoperative continuous positive airway pressure to prevent pneumonia, re-intubation, and death after major abdominal surgery (PRISM): a multicentre, open-label, randomised, phase 3 trial.1 passage
• Pragmatic methods to avoid intensive care unit admission when it does not align with patient and family goals.1 passage
• Precision medicine in obstructive sleep apnoea.1 passage
• Precision respiratory medicine and the microbiome.1 passage
• Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies.1 passage
• Prediction of mortality in patients with chronic obstructive pulmonary disease with the new Global Initiative for Chronic Obstructive Lung Disease 2017 classification: a cohort study.1 passage
• Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial.1 passage
• Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies.1 passage
• Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials.1 passage
• Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial.1 passage
• Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.1 passage
• Prehospital antibiotics in the ambulance for sepsis: a multicentre, open label, randomised trial.1 passage
• Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.1 passage
• Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study.1 passage
• Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study.1 passage
• Prevalence and risk factors of small airway dysfunction, and association with smoking, in China: findings from a national cross-sectional study.1 passage
• Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study.1 passage
• Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study.1 passage
• Prevalence, risk factors, and clinical implications of preserved ratio impaired spirometry: a UK Biobank cohort analysis.1 passage
• Prevention and care of respiratory failure in obese patients.1 passage
• Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia.1 passage
• Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial.1 passage
• Primary ciliary dyskinesia in the genomics age.1 passage
• Prognosis of asymptomatic and symptomatic, undiagnosed COPD in the general population in Denmark: a prospective cohort study.1 passage
• Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials.1 passage
• Prognostic value of transbronchial lung cryobiopsy for the multidisciplinary diagnosis of idiopathic pulmonary fibrosis: a retrospective validation study.1 passage
• Progress in therapies for cystic fibrosis.1 passage
• Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities.1 passage
• Pulmonary alveolar proteinosis in adults: pathophysiology and clinical approach.1 passage
• Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans.1 passage
• Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study.1 passage
• Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial.1 passage
• Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy.1 passage
• Pulmonary hypertension associated with idiopathic interstitial pneumonia: is effective pharmacotherapy an impossible dream?1 passage
• Pulmonary sarcoidosis.1 passage
• Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study.1 passage
• Rapid, comprehensive, and affordable mycobacterial diagnosis with whole-genome sequencing: a prospective study.1 passage
• Regular versus as-needed budesonide and formoterol combination treatment for moderate asthma: a non-inferiority, randomised, double-blind clinical trial.1 passage
• Relation between circulating CC16 concentrations, lung function, and development of chronic obstructive pulmonary disease across the lifespan: a prospective study.1 passage
• Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial.1 passage
• Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.1 passage
• Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial.1 passage
• Restricted versus continued standard caloric intake during the management of refeeding syndrome in critically ill adults: a randomised, parallel-group, multicentre, single-blind controlled trial.1 passage
• Retraction and republication-Effect of early versus late or no tracheostomy on mortality of critically ill patients receiving mechanical ventilation: a systematic review and meta-analysis.1 passage
• Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study.1 passage
• Risk of COVID-19 hospital admission among children aged 5-17 years with asthma in Scotland: a national incident cohort study.1 passage
• Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform.1 passage
• Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK.1 passage
• Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.1 passage
• Role of thoracic ultrasonography in pleurodesis pathways for malignant pleural effusions (SIMPLE): an open-label, randomised controlled trial.1 passage
• Rosuvastatin versus placebo for delirium in intensive care and subsequent cognitive impairment in patients with sepsis-associated acute respiratory distress syndrome: an ancillary study to a randomised controlled trial.1 passage
• Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial.1 passage
• Routine monitoring with pleural manometry during therapeutic large-volume thoracentesis to prevent pleural-pressure-related complications: a multicentre, single-blind randomised controlled trial.1 passage
• Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial.1 passage
• SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study.1 passage
• Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials.1 passage
• Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.1 passage
• Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial.1 passage
• Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study.1 passage
• Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon γ release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial.1 passage
• Safety and efficacy of tiotropium in children aged 1-5 years with persistent asthmatic symptoms: a randomised, double-blind, placebo-controlled trial.1 passage
• Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan.1 passage
• Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial.1 passage
• Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.1 passage
• Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.1 passage
• Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial.1 passage
• Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial.1 passage
• Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.1 passage
• Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.1 passage
• Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.1 passage
• Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.1 passage
• Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial.1 passage
• Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial.1 passage
• Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial.1 passage
• Sedation and analgesia practices in neonatal intensive care units (EUROPAIN): results from a prospective cohort study.1 passage
• Segmental volume reduction using thermal vapour ablation in patients with severe emphysema: 6-month results of the multicentre, parallel-group, open-label, randomised controlled STEP-UP trial.1 passage
• Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial.1 passage
• Sepsis-associated acute respiratory distress syndrome in individuals of European ancestry: a genome-wide association study.1 passage
• Sepsis: older and newer concepts.1 passage
• Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study.1 passage
• Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.1 passage
• Severe respiratory illness associated with a nationwide outbreak of enterovirus D68 in the USA (2014): a descriptive epidemiological investigation.1 passage
• Sexual and reproductive health in cystic fibrosis: a life-course perspective.1 passage
• Shared and distinct genetic risk factors for childhood-onset and adult-onset asthma: genome-wide and transcriptome-wide studies.1 passage
• Sleep apnoea and the brain: a complex relationship.1 passage
• Small airway loss in the physiologically ageing lung: a cross-sectional study in unused donor lungs.1 passage
• Small airways disease in mild and moderate chronic obstructive pulmonary disease: a cross-sectional study.1 passage
• Small airways pathology in idiopathic pulmonary fibrosis: a retrospective cohort study.1 passage
• Spontaneous pneumothorax: time to rethink management?1 passage
• Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies.1 passage
• Staff education, regular sedation and analgesia quality feedback, and a sedation monitoring technology for improving sedation and analgesia quality for critically ill, mechanically ventilated patients: a cluster randomised trial.1 passage
• Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial.1 passage
• Subphenotypes in critical care: translation into clinical practice.1 passage
• Surgical and endoscopic interventions that reduce lung volume for emphysema: a systemic review and meta-analysis.1 passage
• Susceptibility to corticosteroid-induced adrenal suppression: a genome-wide association study.1 passage
• Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial.1 passage
• Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.1 passage
• Systemic sclerosis-associated interstitial lung disease.1 passage
• Targeted case finding for chronic obstructive pulmonary disease versus routine practice in primary care (TargetCOPD): a cluster-randomised controlled trial.1 passage
• Targeting of MEK in lung cancer therapeutics.1 passage
• Telomere length and risk of idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease: a mendelian randomisation study.1 passage
• Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.1 passage
• The Acute COPD Exacerbation Prediction Tool (ACCEPT): a modelling study.1 passage
• The Berlin definition of acute respiratory distress syndrome: should patients receiving high-flow nasal oxygen be included?1 passage
• The CF-Sputum Induction Trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial.1 passage
• The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity.1 passage
• The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis.1 passage
• The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study.1 passage
• The Montreux definition of neonatal ARDS: biological and clinical background behind the description of a new entity.1 passage
• The NoSAS score for screening of sleep-disordered breathing: a derivation and validation study.1 passage
• The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases?1 passage
• The challenge of reducing smoking in people with serious mental illness.1 passage
• The diagnosis of idiopathic pulmonary fibrosis: current and future approaches.1 passage
• The effect of an electronic monitoring device with audiovisual reminder function on adherence to inhaled corticosteroids and school attendance in children with asthma: a randomised controlled trial.1 passage
• The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis.1 passage
• The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.1 passage
• The future of cystic fibrosis care: a global perspective.1 passage
• The genetics of asthma and the promise of genomics-guided drug target discovery.1 passage
• The global burden of paediatric and neonatal sepsis: a systematic review.1 passage
• The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era.1 passage
• The heterogeneity of chronic cough: a case for endotypes of cough hypersensitivity.1 passage
• The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.1 passage
• The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease.1 passage
• The microbiome and critical illness.1 passage
• The microbiome and tuberculosis: state of the art, potential applications, and defining the clinical research agenda.1 passage
• The nasal microbiota in infants with cystic fibrosis in the first year of life: a prospective cohort study.1 passage
• The role of glucocorticoids as adjunctive treatment for sepsis in the modern era.1 passage
• The role of growth and nutrition in the early origins of spirometric restriction in adult life: a longitudinal, multicohort, population-based study.1 passage
• The social network of cystic fibrosis centre care and shared Pseudomonas aeruginosa strain infection: a cross-sectional analysis.1 passage
• The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study.1 passage
• Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities.1 passage
• Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?1 passage
• Time-varying intensity of mechanical ventilation and mortality in patients with acute respiratory failure: a registry-based, prospective cohort study.1 passage
• Timing of onset and burden of persistent critical illness in Australia and New Zealand: a retrospective, population-based, observational study.1 passage
• Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial.1 passage
• Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials.1 passage
• Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.1 passage
• Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial.1 passage
• Towards optimal treatment for latent Mycobacterium tuberculosis infection.1 passage
• Tracheostomy in the COVID-19 era: global and multidisciplinary guidance.1 passage
• Trajectories of asthma and allergies from 7 years to 53 years and associations with lung function and extrapulmonary comorbidity profiles: a prospective cohort study.1 passage
• Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials.1 passage
• Treatment of pulmonary hypertension.1 passage
• Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.1 passage
• Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.1 passage
• Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study.1 passage
• Trends in mortality related to pulmonary embolism in the European Region, 2000-15: analysis of vital registration data from the WHO Mortality Database.1 passage
• Trends in smoking prevalence and implication for chronic diseases in China: serial national cross-sectional surveys from 2003 to 2013.1 passage
• Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.1 passage
• Tropism, replication competence, and innate immune responses of influenza virus: an analysis of human airway organoids and ex-vivo bronchus cultures.1 passage
• Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures.1 passage
• Tuberculosis as a cause or comorbidity of childhood pneumonia in tuberculosis-endemic areas: a systematic review.1 passage
• Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies.1 passage
• Understanding irresponsible use of intensive care unit resources in the USA.1 passage
• Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study.1 passage
• Use of fibrinolytics and deoxyribonuclease in adult patients with pleural empyema: a consensus statement.1 passage
• Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial.1 passage
• Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study.1 passage
• Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.1 passage
• Variations in end-of-life practices in intensive care units worldwide (Ethicus-2): a prospective observational study.1 passage
• Venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review and meta-analysis.1 passage
• Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COVID): a national, multicentre, observational cohort study.1 passage
• Ventilatory support after extubation in critically ill patients.1 passage
• Vitamin D supplementation to prevent asthma exacerbations: a systematic review and meta-analysis of individual participant data.1 passage
• Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease (ViDiCO): a multicentre, double-blind, randomised controlled trial.1 passage
• Whole-genome sequencing for identification of Mendelian disorders in critically ill infants: a retrospective analysis of diagnostic and clinical findings.1 passage
• Xpert MTB/RIF Ultra and Xpert MTB/RIF for diagnosis of tuberculosis in an HIV-endemic setting with a high burden of previous tuberculosis: a two-cohort diagnostic accuracy study.1 passage
• Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in children: a systematic review and meta-analysis.1 passage